Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Argos Therapeutics
Biotech
Argos abandons kidney cancer vaccine after phase 3 fail
Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.
Amirah Al Idrus
Apr 19, 2018 10:01am
Argos kidney cancer vax fails phase 3 futility review, future in doubt
Feb 22, 2017 8:41am
Argos taps Adaptive for help characterizing immune responses to its drugs
Jun 17, 2016 6:06am
